Oncolytics Biotech Net Worth
Oncolytics Biotech Net Worth Breakdown | ONCY |
Oncolytics Biotech Net Worth Analysis
Oncolytics Biotech's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Oncolytics Biotech's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Oncolytics Biotech's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Oncolytics Biotech's net worth analysis. One common approach is to calculate Oncolytics Biotech's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Oncolytics Biotech's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Oncolytics Biotech's net worth. This approach calculates the present value of Oncolytics Biotech's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Oncolytics Biotech's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Oncolytics Biotech's net worth. This involves comparing Oncolytics Biotech's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Oncolytics Biotech's net worth relative to its peers.
Enterprise Value |
|
To determine if Oncolytics Biotech is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Oncolytics Biotech's net worth research are outlined below:
| Oncolytics Biotech generated a negative expected return over the last 90 days | |
| Oncolytics Biotech has some characteristics of a very speculative penny stock | |
| Oncolytics Biotech has high historical volatility and very poor performance | |
| Net Loss for the year was (27.75 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Oncolytics Biotech currently holds about 32.36 M in cash with (28.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.55. | |
| Oncolytics Biotech has a poor financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: Breast Cancer Brachytherapy Market Sees 1.88 Billion Opportunity by 2035 Elekta, Varian Medical Systems, and Isoray Dominate the Competitive Landscape |
Oncolytics Biotech uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Oncolytics Biotech. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Oncolytics Biotech's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 1st of March 2024 Upcoming Quarterly Report | View | |
| 3rd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 1st of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Oncolytics Biotech's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Oncolytics Biotech is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Oncolytics Biotech backward and forwards among themselves. Oncolytics Biotech's institutional investor refers to the entity that pools money to purchase Oncolytics Biotech's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 26.5 K | Seacrest Wealth Management, Llc | 2024-09-30 | 26 K | Brave Asset Management Inc | 2024-09-30 | 25 K | Ubs Group Ag | 2024-09-30 | 22.9 K | Newman Dignan & Sheerar Inc | 2024-09-30 | 22 K | Financial Advisory Corp /ut/ /adv | 2024-09-30 | 20.6 K | Lpl Financial Corp | 2024-09-30 | 20.5 K | Head & Associates, Llc | 2024-09-30 | 17.4 K | Federation Des Caisses Desjardins Du Quebec | 2024-09-30 | 15.8 K | Seeds Investor Llc | 2024-09-30 | 189.9 K | International Assets Investment Management, Llc | 2024-09-30 | 174.3 K |
Follow Oncolytics Biotech's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 64.63 M.Market Cap |
|
Project Oncolytics Biotech's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.82) | (0.86) | |
| Return On Capital Employed | (1.12) | (1.18) | |
| Return On Assets | (0.82) | (0.86) | |
| Return On Equity | (0.91) | (0.86) |
When accessing Oncolytics Biotech's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Oncolytics Biotech's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Oncolytics Biotech's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Oncolytics Biotech's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Oncolytics Biotech. Check Oncolytics Biotech's Beneish M Score to see the likelihood of Oncolytics Biotech's management manipulating its earnings.
Evaluate Oncolytics Biotech's management efficiency
Oncolytics Biotech has return on total asset (ROA) of (0.7133) % which means that it has lost $0.7133 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.3822) %, meaning that it created substantial loss on money invested by shareholders. Oncolytics Biotech's management efficiency ratios could be used to measure how well Oncolytics Biotech manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.86 in 2025. Return On Capital Employed is likely to drop to -1.18 in 2025. At this time, Oncolytics Biotech's Other Current Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 32 M in 2025, whereas Total Assets are likely to drop slightly above 30.5 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.47 | 0.45 | |
| Tangible Book Value Per Share | 0.47 | 0.45 | |
| Enterprise Value Over EBITDA | (2.23) | (2.35) | |
| Price Book Value Ratio | 4.93 | 5.18 | |
| Enterprise Value Multiple | (2.23) | (2.35) | |
| Price Fair Value | 4.93 | 5.18 | |
| Enterprise Value | 96.2 M | 118 M |
Oncolytics Biotech showcases strong leadership that adapts to market changes and drives innovation. Our analysis explores how this adaptability affects the stock's investment appeal.
Oncolytics Biotech time-series forecasting models is one of many Oncolytics Biotech's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Oncolytics Biotech's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Oncolytics Biotech Earnings per Share Projection vs Actual
Oncolytics Biotech Corporate Management
| Amy Levin | Vice Operations | Profile | |
| FCA FCA | Consultant | Profile | |
| Jon Patton | Director Communication | Profile | |
| FACP FACP | Consultant | Profile | |
| Wayne MBA | Interim Board | Profile | |
| Andrew Guttadauro | Global Inc | Profile |
Additional Tools for Oncolytics Stock Analysis
When running Oncolytics Biotech's price analysis, check to measure Oncolytics Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncolytics Biotech is operating at the current time. Most of Oncolytics Biotech's value examination focuses on studying past and present price action to predict the probability of Oncolytics Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncolytics Biotech's price. Additionally, you may evaluate how the addition of Oncolytics Biotech to your portfolios can decrease your overall portfolio volatility.